Anika Therapeutics, Inc. (ANIK) NASDAQ

14.24

+0.13(+0.92%)

Updated at March 19 11:57AM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Cheryl Renee Blanchard	President, Chief Executive Officer & Director	1.27M	1964
David Colleran	Executive VP, General Counsel & Corporate Secretary	685,104	1972
Stephen D. Griffin	Executive Vice President, Chief Financial Officer & Chief Operating Officer	795,171	1986
Ben Joseph	Vice President of Commercial & Corporate Development	0	N/A
Ian W. McLeod	VP & Chief Accounting Officer	0	N/A
James Chase	Senior Vice President of International Sales & Marketing	0	N/A
Mark Namaroff	Vice President of Investor Relations, ESG & Corporate Communications	0	1963
Matthew Hall	Director of Corporate Development & Investor Relations	0	N/A
Lisa Funiciello	Vice President of Human Resources	0	N/A
Mira Leiwant	Senior Vice President of Regulatory, Quality & Clinical Affairs	0	N/A

Name

Title

Pay

Year Born

Cheryl Renee Blanchard

President, Chief Executive Officer & Director

1.27M

1964

David Colleran

Executive VP, General Counsel & Corporate Secretary

685,104

1972

Stephen D. Griffin

Executive Vice President, Chief Financial Officer & Chief Operating Officer

795,171

1986

Ben Joseph

Vice President of Commercial & Corporate Development

N/A

Ian W. McLeod

VP & Chief Accounting Officer

N/A

James Chase

Senior Vice President of International Sales & Marketing

N/A

Mark Namaroff

Vice President of Investor Relations, ESG & Corporate Communications

1963

Matthew Hall

Director of Corporate Development & Investor Relations

N/A

Lisa Funiciello

Vice President of Human Resources

N/A

Mira Leiwant

Senior Vice President of Regulatory, Quality & Clinical Affairs

N/A

Description

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.